arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ARROWHEAD PHARMACEUTICALS, INC.

ARWR
$57.45 ▼ -4.23 (-6.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
84 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Neutral
auto_awesome

Analytical Summary

ARROWHEAD PHARMACEUTICALS, INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $8.2B
Dividend Yield —
Revenue Growth 171.0% ↗
Op. Margin -226.0% ↘
ROIC -36.5% ↘
FCF / Share $-1.26 ↘
Trailing P/E —
Price / Book 17.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

84-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$75.25M
↑ +171.0% —
Net Income Profit after all expenses
$-194.28M
↓ -10.9% —
Operating Margin Operating profit as % of sales
-226.0%
↓ -18.0% 61th
FCF / Share Free cash flow per share
$-1.26
↓ -320.0% —

Health Breakdown

Profitability ↑
57
Returns ↑
43
Financial Health
100
Cash Quality ↓
0

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 23 years · 84 quarters